Halozyme Therapeutics to Host Analyst Meeting in New York on October 15

SAN DIEGO--(BUSINESS WIRE)--Oct. 8, 2009-- Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a meeting for analysts and investors on October 15 in New York. During the meeting, Halozyme's management will present a review of its proprietary product development pipeline, business alliances with Roche and Baxter, and new discoveries in research.

Presenters at the meeting will include Jonathan Lim, M.D., president and CEO, Gregory I. Frost, Ph.D., chief scientific officer, Robert Little, chief commercial officer, and Doug Muchmore, M.D., vice president, endocrinology clinical development. Additional members of the management team will also be attending the meeting.

Halozyme will conduct a live webcast of the presentations beginning at 12:30 p.m. EDT. To access the webcast over the Internet, please go to the company Web site at https://www.halozyme.com. An archive of the presentation will be available on Halozyme's Web site shortly after the conclusion of the meeting.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze technology to Baxter's biological therapeutic compound, GAMMAGARD Liquid®. The product candidates in Halozyme's research pipeline target multiple areas of significant unmet medical need. For more information visit https://www.halozyme.com.

Source: Halozyme Therapeutics, Inc.

HalozymeRobert H. UhlSenior Director, Investor [email protected]